Patient Partnership Index: ‘We Can’t Do It Alone’
David Peacock, MSD UK’s managing director, shares his thoughts on why companies should enter the Patient Partnership Index
2nd July 2020
Web Exclusives
Battling the cytokine storm
A look at some of pharma's approaches to addressing the potentially deadly hyperinflammation seen in some patients with COVID-19
25th June 2020
The need for digitalisation of pharma R&D
If COVID-19 has taught us anything, it’s that we need speed and accuracy now, and digitalisation could help
24th June 2020
US clinical R&D hits new highs
COVID-19 has disrupted clinical trial activity but has simultaneously unleashed a flurry of new innovations that will continue to drive growth in the field, says Murray Aitken
15th June 2020
A matter of life and death
Healthcare staffing in a pandemic: the role of big data, analytics, cloud computing and visualisation
11th June 2020
Building a domestic manufacturing capacity
The importance of the UK building a domestic pharmaceutical and vaccine manufacturing sector, both in the context of COVID-19 and exiting the EU
9th June 2020
Engaging neurodivergent talent for pharma roles
Neurodivergent individuals are systematically overlooked in recruitment processes but are a talent pool that could be highly valuable to the pharma sector, says Marita Hazeldene
26th May 2020
The coronavirus challenge
Brendan Shaw says COVID-19 has tested fragility and resilience in our health systems - and we have failed
15th May 2020
Stepping up
Victoria Langdon says it's time for big pharma to step up…or risk losing out to big tech
14th May 2020
Returning to productivity post COVID-19
Accenture's Brad Michel considers how life sciences companies can begin to re-open as we tentatively move to easing lockdown restrictions
13th May 2020
Design isn’t a fishhook, it’s Velcro
GSK's Andrew Barraclough considers why brands should make design core to their strategy
30th April 2020
Decoding the microbiome
Decoding the microbiome will be an important facet of precision medicine, helping to find the areas of research it could complement and extend
18th April 2020
Transforming clinical trials during COVID-19
While the effort to treat and manage COVID-19 is underway, here’s how companies can also stay focused on developing treatments for all patients
14th April 2020
Six 2020 predictions for real-world evidence
What can we expect to see for real world evidence in 2020 and beyond?
20th March 2020
The disproportional economic impact of cancer on women
More than half of women take home less pay after a cancer diagnosis. It is time to talk about the ‘ripple effect’ of a cancer diagnosis, says Pfizer's Dr Olivia Ashman
8th March 2020
